{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T03:40:24Z","timestamp":1788838824000,"version":"build-2803163510"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82150101"],"award-info":[{"award-number":["82150101"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81872332"],"award-info":[{"award-number":["81872332"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070225"],"award-info":[{"award-number":["82070225"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University-Enterprise Integration Plan of Yantai","award":["2021XDRHXMQT17"],"award-info":[{"award-number":["2021XDRHXMQT17"]}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["6629-21"],"award-info":[{"award-number":["6629-21"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000928","name":"Welch Foundation","doi-asserted-by":"publisher","award":["AU-0042-20030616"],"award-info":[{"award-number":["AU-0042-20030616"]}],"id":[{"id":"10.13039\/100000928","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR202103070011"],"award-info":[{"award-number":["ZR202103070011"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2023QC190"],"award-info":[{"award-number":["ZR2023QC190"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Leukocyte Ig-like receptor B family 4 (LILRB4) as an immune checkpoint on myeloid cells is a potential target for tumor therapy. Extensive osteolytic bone lesion is the most characteristic feature of multiple myeloma. It is unclear whether ectopic LILRB4 on multiple myeloma regulates bone lesion.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The conditioned medium (CM) from <jats:italic>LILRB4<\/jats:italic>-WT and -KO cells was used to analyze the effects of LILRB4 on osteoclasts and osteoblasts. Xenograft, syngeneic and patient derived xenograft models were constructed, and micro-CT, H&amp;E staining were used to observe the bone lesion. RNA-seq, cytokine array, qPCR, the activity of luciferase, Co-IP and western blotting were used to clarify the mechanism by which LILRB4 mediated bone damage in multiple myeloma.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We comprehensively analyzed the expression of LILRB4 in various tumor tissue arrays, and found that LILRB4 was highly expressed in multiple myeloma samples. The patient\u2019s imaging data showed that the higher the expression level of LILRB4, the more serious the bone lesion in patients with multiple myeloma. The conditioned medium from <jats:italic>LILRB4<\/jats:italic>-WT not -KO cells could significantly promote the differentiation and maturation of osteoclasts. Xenograft, syngeneic and patient derived xenograft models furtherly confirmed that LILRB4 could mediate bone lesion of multiple myeloma. Next, cytokine array was performed to identify the differentially expressed cytokines, and RELT was identified and regulated by LILRB4. The overexpression or exogenous RELT could regenerate the bone damage in <jats:italic>LILRB4<\/jats:italic>-KO cells <jats:italic>in vitro<\/jats:italic> and <jats:italic>in vivo<\/jats:italic>. The deletion of <jats:italic>LILRB4<\/jats:italic>, anti-LILRB4 alone or in combination with bortezomib could significantly delay the progression of bone lesion of multiple myeloma.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our findings indicated that LILRB4 promoted the bone lesion by promoting the differentiation and mature of osteoclasts through secreting RELT, and blocking LILRB4 singling pathway could inhibit the bone lesion.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13046-024-03110-y","type":"journal-article","created":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T02:02:11Z","timestamp":1719885731000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["LILRB4 on multiple myeloma cells promotes bone lesion by p-SHP2\/NF-\u03baB\/RELT signal pathway"],"prefix":"10.1186","volume":"43","author":[{"given":"Hongying","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiwen","family":"Luan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiling","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhao","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiashen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianhui","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangmin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dapeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shujuan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siman","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changzhu","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaopeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng Cheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zunling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,1]]},"reference":[{"key":"3110_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00284-8","author":"T Martin","year":"2022","unstructured":"Martin T, Lin Y, Agha M, Cohen AD, Htut M, Stewart AK, et al. Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\u20132, open-label study. The Lancet Haematology. 2022. https:\/\/doi.org\/10.1016\/S2352-3026(22)00284-8.","journal-title":"The Lancet Haematology"},{"issue":"3","key":"3110_CR2","doi-asserted-by":"publisher","first-page":"e119","DOI":"10.1016\/S1470-2045(20)30559-3","volume":"22","author":"E Terpos","year":"2021","unstructured":"Terpos E, Zamagni E, Lentzsch S, Drake MT, Garcia-Sanz R, Abildgaard N, et al. Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group. Lancet Oncol. 2021;22(3):e119\u201330. https:\/\/doi.org\/10.1016\/S1470-2045(20)30559-3.","journal-title":"Lancet Oncol"},{"key":"3110_CR3","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014749","author":"E Menu","year":"2022","unstructured":"Menu E, Vanderkerken K. Exosomes in Multiple Myeloma: from bench to bedside. Blood. 2022. https:\/\/doi.org\/10.1182\/blood.2021014749.","journal-title":"Blood"},{"issue":"7","key":"3110_CR4","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1182\/blood-2004-01-0236","volume":"104","author":"Y Mori","year":"2004","unstructured":"Mori Y, Shimizu N, Dallas M, Niewolna M, Story B, Williams PJ, et al. Anti-alpha4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis. Blood. 2004;104(7):2149\u201354. https:\/\/doi.org\/10.1182\/blood-2004-01-0236.","journal-title":"Blood"},{"issue":"1","key":"3110_CR5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41408-017-0037-4","volume":"8","author":"E Terpos","year":"2018","unstructured":"Terpos E, Ntanasis-Stathopoulos I, Gavriatopoulou M, Dimopoulos MA. Pathogenesis of bone disease in multiple myeloma: from bench to bedside. Blood Cancer J. 2018;8(1):7. https:\/\/doi.org\/10.1038\/s41408-017-0037-4.","journal-title":"Blood Cancer J"},{"issue":"10272","key":"3110_CR6","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","volume":"397","author":"N van de Donk","year":"2021","unstructured":"van de Donk N, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021;397(10272):410\u201327. https:\/\/doi.org\/10.1016\/S0140-6736(21)00135-5.","journal-title":"Lancet"},{"issue":"2","key":"3110_CR7","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1182\/blood.v97.2.346","volume":"97","author":"F Sanz-Rodriguez","year":"2001","unstructured":"Sanz-Rodriguez F, Hidalgo A, Teixido J. Chemokine stromal cell-derived factor-1alpha modulates VLA-4 integrin-mediated multiple myeloma cell adhesion to CS-1\/fibronectin and VCAM-1. Blood. 2001;97(2):346\u201351. https:\/\/doi.org\/10.1182\/blood.v97.2.346.","journal-title":"Blood"},{"issue":"6","key":"3110_CR8","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41408-020-0331-4","volume":"10","author":"P Nair-Gupta","year":"2020","unstructured":"Nair-Gupta P, Rudnick SI, Luistro L, Smith M, McDaid R, Li Y, et al. Blockade of VLA4 sensitizes leukemic and myeloma tumor cells to CD3 redirection in the bone marrow microenvironment. Blood Cancer J. 2020;10(6):65. https:\/\/doi.org\/10.1038\/s41408-020-0331-4.","journal-title":"Blood Cancer J"},{"issue":"18","key":"3110_CR9","doi-asserted-by":"publisher","first-page":"4679","DOI":"10.1158\/0008-5472.CAN-19-0343","volume":"79","author":"PSY Chong","year":"2019","unstructured":"Chong PSY, Zhou J, Lim JSL, Hee YT, Chooi JY, Chung TH, et al. IL6 Promotes a STAT3-PRL3 Feedforward Loop via SHP2 Repression in Multiple Myeloma. Can Res. 2019;79(18):4679\u201388. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-0343.","journal-title":"Can Res"},{"issue":"2","key":"3110_CR10","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1158\/0008-5472.CAN-12-2280","volume":"73","author":"BJ Schmiedel","year":"2013","unstructured":"Schmiedel BJ, Scheible CA, Nuebling T, Kopp HG, Wirths S, Azuma M, et al. RANKL expression, function, and therapeutic targeting in multiple myeloma and chronic lymphocytic leukemia. Can Res. 2013;73(2):683\u201394. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-2280.","journal-title":"Can Res"},{"issue":"1","key":"3110_CR11","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1158\/1078-0432.CCR-18-1537","volume":"25","author":"NS Raje","year":"2019","unstructured":"Raje NS, Bhatta S, Terpos E. Role of the RANK\/RANKL Pathway in Multiple Myeloma. Clinical cancer research\u202f: an official journal of the American Association for Cancer Research. 2019;25(1):12\u201320. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-1537.","journal-title":"Clinical cancer research : an official journal of the American Association for Cancer Research"},{"issue":"11","key":"3110_CR12","doi-asserted-by":"publisher","first-page":"e500","DOI":"10.1038\/bcj.2016.108","volume":"6","author":"E Spanoudakis","year":"2016","unstructured":"Spanoudakis E, Papoutselis M, Terpos E, Dimopoulos MA, Tsatalas C, Margaritis D, et al. Overexpression of RANKL by invariant NKT cells enriched in the bone marrow of patients with multiple myeloma. Blood Cancer J. 2016;6(11):e500. https:\/\/doi.org\/10.1038\/bcj.2016.108.","journal-title":"Blood Cancer J"},{"issue":"3","key":"3110_CR13","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1182\/blood-2003-02-0380","volume":"102","author":"E Terpos","year":"2003","unstructured":"Terpos E, Szydlo R, Apperley JF, Hatjiharissi E, Politou M, Meletis J, et al. Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood. 2003;102(3):1064\u20139. https:\/\/doi.org\/10.1182\/blood-2003-02-0380.","journal-title":"Blood"},{"issue":"3","key":"3110_CR14","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S1470-2045(18)30075-5","volume":"19","author":"MA Dimopoulos","year":"2018","unstructured":"Dimopoulos MA, Kastritis E. Denosumab for myeloma bone disease: ready for prime time? Lancet Oncol. 2018;19(3):277\u20138. https:\/\/doi.org\/10.1016\/S1470-2045(18)30075-5.","journal-title":"Lancet Oncol"},{"issue":"3","key":"3110_CR15","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","volume":"19","author":"N Raje","year":"2018","unstructured":"Raje N, Terpos E, Willenbacher W, Shimizu K, Garcia-Sanz R, Durie B, et al. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. Lancet Oncol. 2018;19(3):370\u201381. https:\/\/doi.org\/10.1016\/S1470-2045(18)30072-X.","journal-title":"Lancet Oncol"},{"issue":"4","key":"3110_CR16","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1158\/1078-0432.CCR-05-1933","volume":"12","author":"JJ Body","year":"2006","unstructured":"Body JJ, Facon T, Coleman RE, Lipton A, Geurs F, Fan M, et al. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clinical cancer research\u202f: an official journal of the American Association for Cancer Research. 2006;12(4):1221\u20138. https:\/\/doi.org\/10.1158\/1078-0432.CCR-05-1933.","journal-title":"Clinical cancer research : an official journal of the American Association for Cancer Research"},{"issue":"11","key":"3110_CR17","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/s41408-020-00378-z","volume":"10","author":"T Yu","year":"2020","unstructured":"Yu T, Chaganty B, Lin L, Xing L, Ramakrishnan B, Wen K, et al. VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo. Blood Cancer J. 2020;10(11):110. https:\/\/doi.org\/10.1038\/s41408-020-00378-z.","journal-title":"Blood Cancer J"},{"issue":"3","key":"3110_CR18","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3109\/08923973.2016.1153110","volume":"38","author":"D Chen","year":"2016","unstructured":"Chen D, Zou J, Zong Y, Meng H, An G, Yang L. Anti-human CD138 monoclonal antibodies and their bispecific formats: generation and characterization. Immunopharmacol Immunotoxicol. 2016;38(3):175\u201383. https:\/\/doi.org\/10.3109\/08923973.2016.1153110.","journal-title":"Immunopharmacol Immunotoxicol"},{"issue":"12","key":"3110_CR19","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.1038\/leu.2017.152","volume":"31","author":"J Delgado-Calle","year":"2017","unstructured":"Delgado-Calle J, Anderson J, Cregor MD, Condon KW, Kuhstoss SA, Plotkin LI, et al. Genetic deletion of Sost or pharmacological inhibition of sclerostin prevent multiple myeloma-induced bone disease without affecting tumor growth. Leukemia. 2017;31(12):2686\u201394. https:\/\/doi.org\/10.1038\/leu.2017.152.","journal-title":"Leukemia"},{"issue":"51","key":"3110_CR20","doi-asserted-by":"publisher","first-page":"40135","DOI":"10.1074\/jbc.M110.166892","volume":"285","author":"H Glantschnig","year":"2010","unstructured":"Glantschnig H, Hampton RA, Lu P, Zhao JZ, Vitelli S, Huang L, et al. Generation and selection of novel fully human monoclonal antibodies that neutralize Dickkopf-1 (DKK1) inhibitory function in vitro and increase bone mass in vivo. J Biol Chem. 2010;285(51):40135\u201347. https:\/\/doi.org\/10.1074\/jbc.M110.166892.","journal-title":"J Biol Chem"},{"issue":"26","key":"3110_CR21","doi-asserted-by":"publisher","first-page":"6871","DOI":"10.1182\/blood-2011-04-346775","volume":"118","author":"S D'Souza","year":"2011","unstructured":"D\u2019Souza S, del Prete D, Jin S, Sun Q, Huston AJ, Kostov FE, et al. Gfi1 expressed in bone marrow stromal cells is a novel osteoblast suppressor in patients with multiple myeloma bone disease. Blood. 2011;118(26):6871\u201380. https:\/\/doi.org\/10.1182\/blood-2011-04-346775.","journal-title":"Blood"},{"issue":"8","key":"3110_CR22","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1056\/NEJMoa1606038","volume":"375","author":"A Palumbo","year":"2016","unstructured":"Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, et al. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2016;375(8):754\u201366. https:\/\/doi.org\/10.1056\/NEJMoa1606038.","journal-title":"N Engl J Med"},{"issue":"6","key":"3110_CR23","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S1470-2045(19)30152-4","volume":"20","author":"PG Richardson","year":"2019","unstructured":"Richardson PG, Oriol A, Beksac M, Liberati AM, Galli M, Schjesvold F, et al. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(6):781\u201394. https:\/\/doi.org\/10.1016\/S1470-2045(19)30152-4.","journal-title":"Lancet Oncol"},{"issue":"14","key":"3110_CR24","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","volume":"376","author":"M Attal","year":"2017","unstructured":"Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, et al. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma. N Engl J Med. 2017;376(14):1311\u201320. https:\/\/doi.org\/10.1056\/NEJMoa1611750.","journal-title":"N Engl J Med"},{"issue":"18","key":"3110_CR25","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, et al. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2019;380(18):1726\u201337. https:\/\/doi.org\/10.1056\/NEJMoa1817226.","journal-title":"N Engl J Med"},{"issue":"2","key":"3110_CR26","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/BS9.0000000000000109","volume":"4","author":"T Yang","year":"2022","unstructured":"Yang T, Qian Y, Liang X, Wu J, Zou M, Deng M. LILRB4, an immune checkpoint on myeloid cells. Blood Sci. 2022;4(2):49\u201356. https:\/\/doi.org\/10.1097\/BS9.0000000000000109.","journal-title":"Blood Sci"},{"issue":"1","key":"3110_CR27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1080\/15384101.2015.1121324","volume":"15","author":"X Kang","year":"2016","unstructured":"Kang X, Kim J, Deng M, John S, Chen H, Wu G, et al. Inhibitory leukocyte immunoglobulin-like receptors: Immune checkpoint proteins and tumor sustaining factors. Cell Cycle. 2016;15(1):25\u201340. https:\/\/doi.org\/10.1080\/15384101.2015.1121324.","journal-title":"Cell Cycle"},{"issue":"3\u20134","key":"3110_CR28","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/s0966-3274(03)00058-3","volume":"11","author":"JS Manavalan","year":"2003","unstructured":"Manavalan JS, Rossi PC, Vlad G, Piazza F, Yarilina A, Cortesini R, et al. High expression of ILT3 and ILT4 is a general feature of tolerogenic dendritic cells. Transpl Immunol. 2003;11(3\u20134):245\u201358. https:\/\/doi.org\/10.1016\/s0966-3274(03)00058-3.","journal-title":"Transpl Immunol"},{"issue":"5","key":"3110_CR29","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.4049\/jimmunol.176.5.2790","volume":"176","author":"S Kim-Schulze","year":"2006","unstructured":"Kim-Schulze S, Scotto L, Vlad G, Piazza F, Lin H, Liu Z, et al. Recombinant Ig-like transcript 3-Fc modulates T cell responses via induction of Th anergy and differentiation of CD8+ T suppressor cells. J Immunol. 2006;176(5):2790\u20138.","journal-title":"J Immunol"},{"issue":"3","key":"3110_CR30","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.4049\/jimmunol.1700553","volume":"200","author":"Z Xu","year":"2018","unstructured":"Xu Z, Chang CC, Li M, Zhang QY, Vasilescu EM, D\u2019Agati V, et al. ILT3.Fc-CD166 Interaction Induces Inactivation of p70 S6 Kinase and Inhibits Tumor Cell Growth. J Immunol. 2018;200(3):1207\u201319. https:\/\/doi.org\/10.4049\/jimmunol.1700553.","journal-title":"J Immunol"},{"issue":"7728","key":"3110_CR31","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/s41586-018-0615-z","volume":"562","author":"M Deng","year":"2018","unstructured":"Deng M, Gui X, Kim J, Xie L, Chen W, Li Z, et al. LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration. Nature. 2018;562(7728):605\u20139. https:\/\/doi.org\/10.1038\/s41586-018-0615-z.","journal-title":"Nature"},{"issue":"3","key":"3110_CR32","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/s41423-019-0321-2","volume":"17","author":"Z Li","year":"2020","unstructured":"Li Z, Deng M, Huang F, Jin C, Sun S, Chen H, et al. LILRB4 ITIMs mediate the T cell suppression and infiltration of acute myeloid leukemia cells. Cell Mol Immunol. 2020;17(3):272\u201382. https:\/\/doi.org\/10.1038\/s41423-019-0321-2.","journal-title":"Cell Mol Immunol"},{"issue":"11","key":"3110_CR33","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1158\/2326-6066.cir-21-0240","volume":"9","author":"KJ Paavola","year":"2021","unstructured":"Paavola KJ, Roda JM, Lin VY, Chen P, O\u2019Hollaren KP, Ventura R, et al. The Fibronectin-ILT3 Interaction Functions as a Stromal Checkpoint that Suppresses Myeloid Cells. Cancer Immunol Res. 2021;9(11):1283\u201397. https:\/\/doi.org\/10.1158\/2326-6066.cir-21-0240.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"3110_CR34","doi-asserted-by":"publisher","first-page":"101374","DOI":"10.1016\/j.xcrm.2023.101374","volume":"5","author":"Y Wang","year":"2024","unstructured":"Wang Y, Sun Y, Deng S, Liu J, Yu J, Chi H, et al. Discovery of galectin-8 as an LILRB4 ligand driving M-MDSCs defines a class of antibodies to fight solid tumors. Cell reports Medicine. 2024;5(1):101374. https:\/\/doi.org\/10.1016\/j.xcrm.2023.101374.","journal-title":"Cell reports Medicine"},{"issue":"7","key":"3110_CR35","doi-asserted-by":"publisher","first-page":"e1014242","DOI":"10.1080\/2162402x.2015.1014242","volume":"4","author":"PL de Goeje","year":"2015","unstructured":"de Goeje PL, Bezemer K, Heuvers ME, Dingemans AC, Groen HJ, Smit EF, et al. Immunoglobulin-like transcript 3 is expressed by myeloid-derived suppressor cells and correlates with survival in patients with non-small cell lung cancer. Oncoimmunology. 2015;4(7):e1014242. https:\/\/doi.org\/10.1080\/2162402x.2015.1014242.","journal-title":"Oncoimmunology"},{"issue":"1","key":"3110_CR36","doi-asserted-by":"publisher","first-page":"2060907","DOI":"10.1080\/2162402X.2022.2060907","volume":"11","author":"MT Su","year":"2022","unstructured":"Su MT, Kumata S, Endo S, Okada Y, Takai T. LILRB4 promotes tumor metastasis by regulating MDSCs and inhibiting miR-1 family miRNAs. Oncoimmunology. 2022;11(1):2060907. https:\/\/doi.org\/10.1080\/2162402X.2022.2060907.","journal-title":"Oncoimmunology"},{"issue":"4","key":"3110_CR37","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1158\/1541-7786.MCR-20-0622","volume":"19","author":"L Singh","year":"2021","unstructured":"Singh L, Muise ES, Bhattacharya A, Grein J, Javaid S, Stivers P, et al. ILT3 (LILRB4) Promotes the Immunosuppressive Function of Tumor-Educated Human Monocytic Myeloid-Derived Suppressor Cells. Mol Cancer Res. 2021;19(4):702\u201316. https:\/\/doi.org\/10.1158\/1541-7786.MCR-20-0622.","journal-title":"Mol Cancer Res"},{"issue":"7","key":"3110_CR38","doi-asserted-by":"publisher","first-page":"e20201811","DOI":"10.1084\/jem.20201811","volume":"218","author":"N Sharma","year":"2021","unstructured":"Sharma N, Atolagbe OT, Ge Z, Allison JP. LILRB4 suppresses immunity in solid tumors and is a potential target for immunotherapy. J Exp Med. 2021;218(7):e20201811. https:\/\/doi.org\/10.1084\/jem.20201811.","journal-title":"J Exp Med"},{"issue":"8","key":"3110_CR39","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1158\/2326-6066.CIR-19-0036","volume":"7","author":"X Gui","year":"2019","unstructured":"Gui X, Deng M, Song H, Chen Y, Xie J, Li Z, et al. Disrupting LILRB4\/APOE Interaction by an Efficacious Humanized Antibody Reverses T-cell Suppression and Blocks AML Development. Cancer Immunol Res. 2019;7(8):1244\u201357. https:\/\/doi.org\/10.1158\/2326-6066.CIR-19-0036.","journal-title":"Cancer Immunol Res"},{"issue":"10","key":"3110_CR40","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1016\/j.ymthe.2018.08.001","volume":"26","author":"S John","year":"2018","unstructured":"John S, Chen H, Deng M, Gui X, Wu G, Chen W, et al. A Novel Anti-LILRB4 CAR-T Cell for the Treatment of Monocytic AML. Mol Ther. 2018;26(10):2487\u201395. https:\/\/doi.org\/10.1016\/j.ymthe.2018.08.001.","journal-title":"Mol Ther"},{"issue":"11","key":"3110_CR41","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1158\/1535-7163.MCT-20-0407","volume":"19","author":"Y Anami","year":"2020","unstructured":"Anami Y, Deng M, Gui X, Yamaguchi A, Yamazaki CM, Zhang N, et al. LILRB4-targeting Antibody-Drug Conjugates for the Treatment of Acute Myeloid Leukemia. Mol Cancer Ther. 2020;19(11):2330\u20139. https:\/\/doi.org\/10.1158\/1535-7163.MCT-20-0407.","journal-title":"Mol Cancer Ther"},{"key":"3110_CR42","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.canlet.2020.10.048","volume":"501","author":"J Li","year":"2021","unstructured":"Li J, Gao A, Zhang F, Wang S, Wang J, Wang J, et al. ILT3 promotes tumor cell motility and angiogenesis in non-small cell lung cancer. Cancer Lett. 2021;501:263\u201376. https:\/\/doi.org\/10.1016\/j.canlet.2020.10.048.","journal-title":"Cancer Lett"},{"key":"3110_CR43","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxac051","author":"MT Su","year":"2022","unstructured":"Su MT, Ono K, Kezuka D, Miyamoto S, Mori Y, Takai T. Fibronectin-LILRB4\/gp49B interaction negatively regulates osteoclastogenesis through inhibition of RANKL-induced TRAF6\/TAK1\/NF-kB\/MAPK signaling. Int Immunol. 2022. https:\/\/doi.org\/10.1093\/intimm\/dxac051.","journal-title":"Int Immunol"},{"issue":"12","key":"3110_CR44","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1093\/intimm\/dxw044","volume":"28","author":"M Inui","year":"2016","unstructured":"Inui M, Sugahara-Tobinai A, Fujii H, Itoh-Nakadai A, Fukuyama H, Kurosaki T, et al. Tolerogenic immunoreceptor ILT3\/LILRB4 paradoxically marks pathogenic auto-antibody-producing plasmablasts and plasma cells in non-treated SLE. Int Immunol. 2016;28(12):597\u2013604. https:\/\/doi.org\/10.1093\/intimm\/dxw044.","journal-title":"Int Immunol"},{"issue":"18","key":"3110_CR45","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1182\/blood-2017-03-775858","volume":"130","author":"V Zurli","year":"2017","unstructured":"Zurli V, Wimmer G, Cattaneo F, Candi V, Cencini E, Gozzetti A, et al. Ectopic ILT3 controls BCR-dependent activation of Akt in B-cell chronic lymphocytic leukemia. Blood. 2017;130(18):2006\u201317. https:\/\/doi.org\/10.1182\/blood-2017-03-775858.","journal-title":"Blood"},{"issue":"7","key":"3110_CR46","doi-asserted-by":"publisher","first-page":"101110","DOI":"10.1016\/j.xcrm.2023.101110","volume":"4","author":"F Di Meo","year":"2023","unstructured":"Di Meo F, Iyer A, Akama K, Cheng R, Yu C, Cesarano A, et al. A target discovery pipeline identified ILT3 as a target for immunotherapy of multiple myeloma. Cell reports Medicine. 2023;4(7):101110. https:\/\/doi.org\/10.1016\/j.xcrm.2023.101110.","journal-title":"Cell reports Medicine"},{"issue":"5","key":"3110_CR47","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1002\/cyto.b.20164","volume":"72","author":"AI Colovai","year":"2007","unstructured":"Colovai AI, Tsao L, Wang S, Lin H, Wang C, Seki T, et al. Expression of inhibitory receptor ILT3 on neoplastic B cells is associated with lymphoid tissue involvement in chronic lymphocytic leukemia. Cytometry B Clin Cytom. 2007;72(5):354\u201362. https:\/\/doi.org\/10.1002\/cyto.b.20164.","journal-title":"Cytometry B Clin Cytom"},{"issue":"10","key":"3110_CR48","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1158\/2326-6066.cir-23-0088","volume":"11","author":"J Wang","year":"2023","unstructured":"Wang J, Peng Z, Guo J, Wang Y, Wang S, Jiang H, et al. CXCL10 Recruitment of \u03b3\u03b4 T Cells into the Hypoxic Bone Marrow Environment Leads to IL17 Expression and Multiple Myeloma Progression. Cancer Immunol Res. 2023;11(10):1384\u201399. https:\/\/doi.org\/10.1158\/2326-6066.cir-23-0088.","journal-title":"Cancer Immunol Res"},{"issue":"8","key":"3110_CR49","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1038\/sj.leu.2403823","volume":"19","author":"S Kumar","year":"2005","unstructured":"Kumar S, Rajkumar SV, Kimlinger T, Greipp PR, Witzig TE. CD45 expression by bone marrow plasma cells in multiple myeloma: clinical and biological correlations. Leukemia. 2005;19(8):1466\u201370. https:\/\/doi.org\/10.1038\/sj.leu.2403823.","journal-title":"Leukemia"},{"issue":"1","key":"3110_CR50","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/cyto.b.21050","volume":"84","author":"H Dobrowolska","year":"2013","unstructured":"Dobrowolska H, Gill KZ, Serban G, Ivan E, Li Q, Qiao P, et al. Expression of immune inhibitory receptor ILT3 in acute myeloid leukemia with monocytic differentiation. Cytometry B Clin Cytom. 2013;84(1):21\u20139. https:\/\/doi.org\/10.1002\/cyto.b.21050.","journal-title":"Cytometry B Clin Cytom"},{"issue":"4","key":"3110_CR51","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/cyto.b.21952","volume":"100","author":"HRO Churchill","year":"2021","unstructured":"Churchill HRO, Fuda FS, Xu J, Deng M, Zhang CC, An Z, et al. Leukocyte immunoglobulin-like receptor B1 and B4 (LILRB1 and LILRB4): Highly sensitive and specific markers of acute myeloid leukemia with monocytic differentiation. Cytometry B Clin Cytom. 2021;100(4):476\u201387. https:\/\/doi.org\/10.1002\/cyto.b.21952.","journal-title":"Cytometry B Clin Cytom"},{"issue":"7","key":"3110_CR52","doi-asserted-by":"publisher","first-page":"4742","DOI":"10.4049\/jimmunol.181.7.4742","volume":"181","author":"Y Mori","year":"2008","unstructured":"Mori Y, Tsuji S, Inui M, Sakamoto Y, Endo S, Ito Y, et al. Inhibitory immunoglobulin-like receptors LILRB and PIR-B negatively regulate osteoclast development. J Immunol. 2008;181(7):4742\u201351.","journal-title":"J Immunol"},{"issue":"5484","key":"3110_CR53","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1126\/science.289.5484.1504","volume":"289","author":"SL Teitelbaum","year":"2000","unstructured":"Teitelbaum SL. Bone resorption by osteoclasts. Science. 2000;289(5484):1504\u20138. https:\/\/doi.org\/10.1126\/science.289.5484.1504.","journal-title":"Science"},{"issue":"12","key":"3110_CR54","doi-asserted-by":"publisher","first-page":"6208","DOI":"10.3390\/ijms22126208","volume":"22","author":"SKR Mukkamalla","year":"2021","unstructured":"Mukkamalla SKR, Malipeddi D. Myeloma Bone Disease: A Comprehensive Review. Int J Mol Sci. 2021;22(12):6208. https:\/\/doi.org\/10.3390\/ijms22126208.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"3110_CR55","doi-asserted-by":"publisher","first-page":"e2219439120","DOI":"10.1073\/pnas.2219439120","volume":"120","author":"W Winkler","year":"2023","unstructured":"Winkler W, Farre Diaz C, Blanc E, Napieczynska H, Langner P, Werner M, et al. Mouse models of human multiple myeloma subgroups. Proc Natl Acad Sci U S A. 2023;120(10):e2219439120. https:\/\/doi.org\/10.1073\/pnas.2219439120.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11\u201312","key":"3110_CR56","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1242\/dmm.003160","volume":"2","author":"JA Fowler","year":"2009","unstructured":"Fowler JA, Mundy GR, Lwin ST, Lynch CC, Edwards CM. A murine model of myeloma that allows genetic manipulation of the host microenvironment. Dis Model Mech. 2009;2(11\u201312):604\u201311. https:\/\/doi.org\/10.1242\/dmm.003160.","journal-title":"Dis Model Mech"},{"issue":"1","key":"3110_CR57","doi-asserted-by":"publisher","first-page":"6648","DOI":"10.1038\/s41467-022-34352-z","volume":"13","author":"T Yoshimoto","year":"2022","unstructured":"Yoshimoto T, Kittaka M, Doan AAP, Urata R, Prideaux M, Rojas RE, et al. Osteocytes directly regulate osteolysis via MYD88 signaling in bacterial bone infection. Nat Commun. 2022;13(1):6648. https:\/\/doi.org\/10.1038\/s41467-022-34352-z.","journal-title":"Nat Commun"},{"issue":"9","key":"3110_CR58","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1182\/blood.v97.9.2702","volume":"97","author":"GL Sica","year":"2001","unstructured":"Sica GL, Zhu G, Tamada K, Liu D, Ni J, Chen L. RELT, a new member of the tumor necrosis factor receptor superfamily, is selectively expressed in hematopoietic tissues and activates transcription factor NF-kappaB. Blood. 2001;97(9):2702\u20137. https:\/\/doi.org\/10.1182\/blood.v97.9.2702.","journal-title":"Blood"},{"issue":"1","key":"3110_CR59","doi-asserted-by":"publisher","first-page":"6037","DOI":"10.1038\/s41467-020-19932-1","volume":"11","author":"C Federico","year":"2020","unstructured":"Federico C, Alhallak K, Sun J, Duncan K, Azab F, Sudlow GP, et al. Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma. Nat Commun. 2020;11(1):6037. https:\/\/doi.org\/10.1038\/s41467-020-19932-1.","journal-title":"Nat Commun"},{"issue":"21","key":"3110_CR60","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1111\/1759-7714.14991","volume":"14","author":"S Kumata","year":"2023","unstructured":"Kumata S, Notsuda H, Su MT, Saito-Koyama R, Tanaka R, Suzuki Y, et al. Prognostic impact of LILRB4 expression on tumor-infiltrating cells in resected non-small cell lung cancer. Thoracic cancer. 2023;14(21):2057\u201368. https:\/\/doi.org\/10.1111\/1759-7714.14991.","journal-title":"Thoracic cancer"},{"issue":"11","key":"3110_CR61","doi-asserted-by":"publisher","first-page":"89","DOI":"10.15698\/cst2022.11.273","volume":"6","author":"B Pati\u00f1o-Escobar","year":"2022","unstructured":"Pati\u00f1o-Escobar B, Ferguson ID, Wiita AP. Unraveling the surface proteomic profile of multiple myeloma to reveal new immunotherapeutic targets and markers of drug resistance. Cell stress. 2022;6(11):89\u201392. https:\/\/doi.org\/10.15698\/cst2022.11.273.","journal-title":"Cell stress"},{"issue":"15","key":"3110_CR62","doi-asserted-by":"publisher","first-page":"4148","DOI":"10.1182\/bloodadvances.2022009477","volume":"7","author":"Z Sun","year":"2023","unstructured":"Sun Z, Ji J, Li Y, Cui Y, Fan L, Li J, et al. Identification of evolutionary mechanisms of myelomatous effusion by single-cell RNA sequencing. Blood Adv. 2023;7(15):4148\u201359. https:\/\/doi.org\/10.1182\/bloodadvances.2022009477.","journal-title":"Blood Adv"},{"issue":"10","key":"3110_CR63","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1002\/eji.201847633","volume":"48","author":"BK Choi","year":"2018","unstructured":"Choi BK, Kim SH, Kim YH, Lee DG, Oh HS, Han C, et al. RELT negatively regulates the early phase of the T-cell response in mice. Eur J Immunol. 2018;48(10):1739\u201349. https:\/\/doi.org\/10.1002\/eji.201847633.","journal-title":"Eur J Immunol"},{"issue":"4","key":"3110_CR64","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1002\/cam4.2055","volume":"8","author":"D Wu","year":"2019","unstructured":"Wu D, Zhang P, Ma J, Xu J, Yang L, Xu W, et al. Serum biomarker panels for the diagnosis of gastric cancer. Cancer Med. 2019;8(4):1576\u201383. https:\/\/doi.org\/10.1002\/cam4.2055.","journal-title":"Cancer Med"},{"issue":"3","key":"3110_CR65","doi-asserted-by":"publisher","first-page":"R40","DOI":"10.1186\/bcr2091","volume":"10","author":"L Zhong","year":"2008","unstructured":"Zhong L, Ge K, Zu JC, Zhao LH, Shen WK, Wang JF, et al. Autoantibodies as potential biomarkers for breast cancer. Breast cancer research\u202f: BCR. 2008;10(3):R40. https:\/\/doi.org\/10.1186\/bcr2091.","journal-title":"Breast cancer research : BCR"},{"issue":"3","key":"3110_CR66","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1182\/blood-2011-04-325225","volume":"119","author":"BB Aggarwal","year":"2012","unstructured":"Aggarwal BB, Gupta SC, Kim JH. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood. 2012;119(3):651\u201365. https:\/\/doi.org\/10.1182\/blood-2011-04-325225.","journal-title":"Blood"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-024-03110-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-024-03110-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-024-03110-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T02:03:16Z","timestamp":1719885796000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-024-03110-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,1]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3110"],"URL":"https:\/\/doi.org\/10.1186\/s13046-024-03110-y","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,1]]},"assertion":[{"value":"21 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients provided written informed consent. All experiments were approved by the Medical Ethics Committee of Binzhou Medical University (No: 2020\u201317), and were performed under the national standards of Institutional Animal Care and Use Committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors consent to publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CC. Z, Z.A, and N.Z. have patents licensed to, holds equity in, and has Sponsored Research Agreements with Immune-Onc Therapeutics, Inc. Other authors have no competing financial interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"183"}}